Literature DB >> 12072534

The EBNA2 polyproline region is dispensable for Epstein-Barr virus-mediated immortalization maintenance.

Alexey V Gordadze1, David Poston, Paul D Ling.   

Abstract

Epstein-Barr virus nuclear antigen 2 (EBNA2) is required for EBV-mediated immortalization of primary human B cells and is a direct transcriptional activator of viral and cellular genes. The prototype EBNA2 protein contains a unique motif in which 43 out of 45 amino acids are prolines (polyproline region [PPR]). Previous genetic analysis has shown that deletion of the PPR resulted in viruses unable to immortalize B cells, although the protein did appear transcriptionally functional (R. Yalamanchili, S. Harada, and E. Kieff, J. Virol. 70:2468-2473, 1996). The PPR's uniqueness and requirement for immortalization make it an attractive therapeutic target. However, the role of this highly unusual motif for immortalization remains enigmatic. We have recently developed a transcomplementation assay that allows both genetic and functional analyses of EBNA2 in EBV-mediated immortalization maintenance (A. V. Gordadze, R. Peng, J. Tan, G. Liu, R. Sutton, B. Kempkes, G. W. Bornkamm, and P. D. Ling, J. Virol. 75:5899-5912, 2001). Surprisingly, we found that DeltaPPR-EBNA2 was able to support B-cell proliferation similar to that of wild-type EBNA2 in this assay, indicating that deletion of the PPR from EBNA2 does not result in a loss of function required for immortalization maintenance. Further analysis of this mutant EBNA2 revealed that it consistently activated the viral LMP1 and LMP2A promoters severalfold better than wild-type EBNA2 in transient cotransfection assays. In addition, one striking difference between lymphoblastoid cell lines expressing wild-type EBNA2 from those expressing DeltaPPR-EBNA2 is that the latter cells have significantly reduced EBV genomic levels. The data are consistent with a model in which lower EBNA2 target gene dosage may be selected for in DeltaPPR-EBNA2-dependent cell lines to compensate for hyperactive stimulation of viral genes, such as LMP-1, which is cytostatic for B cells when overexpressed. It is conceivable that the hyperactivity rather than the loss of function, as hypothesized previously, could be responsible for the inability of recombinant DeltaPPR-EBNA2 EBVs to immortalize B cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12072534      PMCID: PMC136302          DOI: 10.1128/jvi.76.14.7349-7355.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  The amino-terminus and membrane-spanning domains of LMP-1 inhibit cell proliferation.

Authors:  A Kaykas; B Sugden
Journal:  Oncogene       Date:  2000-03-09       Impact factor: 9.867

2.  SKIP, a CBF1-associated protein, interacts with the ankyrin repeat domain of NotchIC To facilitate NotchIC function.

Authors:  S Zhou; M Fujimuro; J J Hsieh; L Chen; A Miyamoto; G Weinmaster; S D Hayward
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

3.  The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell.

Authors:  G J Babcock; D Hochberg; A D Thorley-Lawson
Journal:  Immunity       Date:  2000-10       Impact factor: 31.745

4.  Epstein-Barr virus nuclear protein 2 has at least two N-terminal domains that mediate self-association.

Authors:  S Harada; R Yalamanchili; E Kieff
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  Regulation of the Epstein-Barr virus C promoter by AUF1 and the cyclic AMP/protein kinase A signaling pathway.

Authors:  E M Fuentes-Pananá; R Peng; G Brewer; J Tan; P D Ling
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  Sequence and functional analysis of EBNA-LP and EBNA2 proteins from nonhuman primate lymphocryptoviruses.

Authors:  R Peng; A V Gordadze; E M Fuentes Pananá; F Wang; J Zong; G S Hayward; J Tan; P D Ling
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

7.  Analysis of C-MYC function in normal cells via conditional gene-targeted mutation.

Authors:  I M de Alboran; R C O'Hagan; F Gärtner; B Malynn; L Davidson; R Rickert; K Rajewsky; R A DePinho; F W Alt
Journal:  Immunity       Date:  2001-01       Impact factor: 31.745

8.  Cell cycle activation by c-myc in a burkitt lymphoma model cell line.

Authors:  A Pajic; D Spitkovsky; B Christoph; B Kempkes; M Schuhmacher; M S Staege; M Brielmeier; J Ellwart; F Kohlhuber; G W Bornkamm; A Polack; D Eick
Journal:  Int J Cancer       Date:  2000-09-15       Impact factor: 7.396

9.  Epstein-barr virus nuclear antigen 3C activates the latent membrane protein 1 promoter in the presence of Epstein-Barr virus nuclear antigen 2 through sequences encompassing an spi-1/Spi-B binding site.

Authors:  B Zhao; C E Sample
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

10.  Evolution of two types of rhesus lymphocryptovirus similar to type 1 and type 2 Epstein-Barr virus.

Authors:  Y G Cho; A V Gordadze; P D Ling; F Wang
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

View more
  10 in total

1.  EBNA2 amino acids 3 to 30 are required for induction of LMP-1 and immortalization maintenance.

Authors:  Alexey V Gordadze; Chisaroka W Onunwor; RongSheng Peng; David Poston; Elisabeth Kremmer; Paul D Ling
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

2.  The Epstein-Barr virus EBNA-LP protein preferentially coactivates EBNA2-mediated stimulation of latent membrane proteins expressed from the viral divergent promoter.

Authors:  Rongsheng Peng; Stephanie C Moses; Jie Tan; Elisabeth Kremmer; Paul D Ling
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

3.  EBNA2 is required for protection of latently Epstein-Barr virus-infected B cells against specific apoptotic stimuli.

Authors:  Jae Myun Lee; Kyoung-Ho Lee; Christopher J Farrell; Paul D Ling; Bettina Kempkes; Jeon Han Park; S Diane Hayward
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

4.  Phase separation of Epstein-Barr virus EBNA2 protein reorganizes chromatin topology for epigenetic regulation.

Authors:  Yiting Yang; Xidong Ye; Ranran Dai; Zhaoqiang Li; Yan Zhang; Wei Xue; Yongchang Zhu; Delong Feng; Litao Qin; Xin Wang; Bo Lei; Shixiu Liao; Bingtao Hao
Journal:  Commun Biol       Date:  2021-08-16

5.  Repression of the proapoptotic cellular BIK/NBK gene by Epstein-Barr virus antagonizes transforming growth factor β1-induced B-cell apoptosis.

Authors:  Eva M Campion; Roya Hakimjavadi; Sinéad T Loughran; Susan Phelan; Sinéad M Smith; Brendan N D'Souza; Rosemary J Tierney; Andrew I Bell; Paul A Cahill; Dermot Walls
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

6.  C-terminal region of EBNA-2 determines the superior transforming ability of type 1 Epstein-Barr virus by enhanced gene regulation of LMP-1 and CXCR7.

Authors:  Laila Cancian; Rachel Bosshard; Walter Lucchesi; Claudio Elgueta Karstegl; Paul J Farrell
Journal:  PLoS Pathog       Date:  2011-07-28       Impact factor: 6.823

7.  Epstein- Barr Virus: Clinical and Epidemiological Revisits and Genetic Basis of Oncogenesis.

Authors:  Abdelwahid Saeed Ali; Mubarak Al-Shraim; Ahmed Musa Al-Hakami; Ian M Jones
Journal:  Open Virol J       Date:  2015-11-03

Review 8.  Epstein-Barr virus-encoded microRNAs as regulators in host immune responses.

Authors:  Man Wang; Fei Yu; Wei Wu; Yu Wang; Han Ding; Lili Qian
Journal:  Int J Biol Sci       Date:  2018-04-05       Impact factor: 6.580

Review 9.  Epstein barr virus encodes miRNAs to assist host immune escape.

Authors:  Weiming Li; Cong He; Jiayi Wu; Dazhi Yang; Weihong Yi
Journal:  J Cancer       Date:  2020-02-03       Impact factor: 4.207

Review 10.  Epstein-Barr virus (EBV)-associated epithelial and non-epithelial lesions of the oral cavity.

Authors:  Kentaro Kikuchi; Harumi Inoue; Yuji Miyazaki; Fumio Ide; Masaru Kojima; Kaoru Kusama
Journal:  Jpn Dent Sci Rev       Date:  2017-03-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.